Category: Uncategorized

Algernon Pharmaceuticals begins screening patients for Phase 2 chronic cough and IPF study   Algernon Pharmaceuticals Inc. (CSE: AGN-OTCQB: AGNPF) CEO Christopher Moreau joined Steve Darling from Proactive Vancouver with news the company has begun screening patients in Australia for a Phase 2 idiopathic pulmonary fibrosis and chronic cough clinical study with their repurposed drug Ifenprodil. Moreau shared details about that study and he also takes a broader look at the drug Ifenprodil and the number of studies the company is undertaking to see it’s effectiveness in treating respiratory conditions. original link: https://ca.proactiveinvestors.com/companies/news/923942/algernon-pharmaceuticals-begins-screening-patients-for-phase-2-chronic-cough-and-ipf-study-923942.html   …

  Algernon Pharmaceuticals (CSE: AGN) gets ethical green light for human trials for COVID-19 fighter Ifenprodil   The scientific process isn’t exactly what you were taught in grade 4. There’s a lot more to it, owing to some historical—well, let’s call them what they are—atrocities, which have taken place as long as white lab-coats have been all the rage in knowledge-defining circles. This process is expensive in both time and money and that’s inherently necessary to impose a modicum of baked-in due-diligence to the process. Getting the right drugs to the right people at the right time isn’t a process …

Algernon Pharmaceuticals receives ethics approval as the company begins clinical trials for Ifenprodil     Algernon Pharmaceuticals Inc. (CSE: AGN-OTCQB: AGNPF) CEO Christopher Moreau joined Steve Darling to announce the company has received ethics approval from a central institutional review board for U.S. study sites for its multinational Phase 2b/3 human study of Ifenprodil for COVID-19. Moreau explains what that means going forward and he also updates the market on the company’s general progress regarding the trials as well as other business activities.   original article: https://ca.proactiveinvestors.com/companies/news/922805/algernon-pharmaceuticals-receives-ethics-approval-as-they-begin-clinical-trials-for-ifenprodil-922805.html …

Human trials approved for B.C. drug company to treat COVID-19   A Vancouver-based drug repurposing company will conduct human trials on patients with acute lung injury in the U.S. and Canada. Chris Moreau, CEO of Algernon Pharmaceuticals Inc., said the U.S. Food and Drug Administration approved the company’s application on June 3 for a human study of its repurposed drug Ifenprodil as a potential therapeutic treatment for patients with COVID-19. Moreau said a doctor-led human trial of the drug was about to start in South Korea, but the planned trial in Canada, the U.S. and possibly Australia would be larger …

Algernon Pharmaceuticals Receives U.S. FDA Clearance for Phase 2b/3 Ifenprodil Human Study     Algernon Pharmaceuticals Inc. (CSE: AGN-OTCQB: AGNPF) CEO Christopher Moreau joined Steve Darling from Proactive Vancouver with major news for the company that they have received clearance from the U.S. FDA for its multinational Phase 2b/3 study of Ifenprodil as a potential treatment for COVID-19. Moreau talks about how big this milestone is for the company and how the study is to be conducted. …

Please find the recording of the BioPub.co video conference held June 1, 2020 entitled Algernon Pharmaceuticals Discusses Multinational Phase 2b/3 Ifenprodil COVID-19 Human Trial on BioPub Webcast Hosted by Dr. KSS MD PhD. About Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) Algernon is a drug re-purposing company that investigates safe, already approved drugs for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing. Algernon …

Small-Cap Pharma Fast-Tracking Repurposed Drug for Covid-19     Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGW:FSE), a Canada-based clinical stage drug development company that focuses on drug repurposing, believes it may have an effective treatment for Covid-19 and is moving ahead with human trials for Ifenprodil, named by Algernon NP-120, in South Korea, Canada, Australia and the U.S. Drug repurposing takes an approved drug and finds new diseases that the drug could treat. Before the coronavirus pandemic hit, Algernon was studying Ifenprodil, which was developed in the 1970s for intermittent claudication, a circulatory disorder of the legs. “It started its life …

Algernon Pharmaceuticals applies for Phase 2b/3 study on Ifenprodil in Australia     Algernon Pharmaceuticals ( CSE: AGN- OTCQB: AGNPF) CEO Christopher Moreau checked in with Steve Darling from Proactive to provide an update on the company as they seek approval in Australia for a Phase 2b/3 study of their repurposed drug Ifenprodil for coronavirus. The company already has approval in Canada and will soon apply in the United States. Moreau telling Proactive when they get approval it will be a Phase 2b study of 100 patients between Australia, Canada and the United States. Then with positive data, the study will …

Algeron Pharmaceuticals in the spotlight with lead drug Ifenprodil as promising coronavirus therapy The company has received the green light from the ministry of food and drug safety in South Korea for a Phase 2 clinical trial of Ifenprodil as a coronavirus (COVID-19) therapy. Algernon Pharmaceuticals Inc (CSE:AGN) (OTCQB:AGNPF) has been nimble — and unusual — in its hunt for a coronavirus (COVID-19) drug. The Vancouver-based drug company has taken a generic neurological drug that Sanofi developed in the 1970’s called Ifenprodil, which is approved for use in South Korea and Japan, and is attempting to repurpose it as a …

Baystreet Staff – Tuesday, April 28, 2020 As Pandemic Progresses, Promising Projects Thrive or Fail in Rally for Effective Coronavirus Treatment The COVID-19 global pandemic united the pharmaceutical world and forced it towards a common goal. Research facilities across the world rally to develop treatments that may mitigate the novel coronavirus’ impact on patients’ well-being. Evaluation processes are being expedited – and research teams discover if their projects move forward, or fail, in shorter time frames than ever before. The main treatment option in the United States, a repurposed drug called chloroquine/hydroxychloroquine, has begun to seem less reliable than originally …